Etonogestrel
- Generic Name
- Etonogestrel
- Brand Names
- Eluryng, Enilloring, Implanon, Nexplanon, Nuvaring
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28O2
- CAS Number
- 54048-10-1
- Unique Ingredient Identifier
- 304GTH6RNH
- Background
Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.
- Indication
Etonogestrel is administered in subdermal implants as long-acting reversible contraception. It is known to be effective in postpartum insertion including breastfeeding women.
Etonogestrel is part of the long-acting contraceptive implants that prevent pregnancy. The implant's effect can remain for 5 years.
- Associated Therapies
- Contraception, Contraceptive implant therapy
Abnormal Uterine Bleeding and Progestin-only Contraceptives
- Conditions
- Contraception
- Interventions
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 390
- Registration Number
- NCT03398811
- Locations
- 🇪🇬
Women Health Hospital - Assiut university, Assiut, Egypt
Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant
- Conditions
- BreastfeedingPost Partum
- Interventions
- First Posted Date
- 2017-11-24
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 60
- Registration Number
- NCT03353012
- Locations
- 🇹🇭
King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand
Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Catherine Anne Chappell
- Target Recruit Count
- 72
- Registration Number
- NCT03282799
- Locations
- 🇺🇬
Infectious Disease Institute, Kampala, Uganda
Nexplanon and Combined Oral Contraceptive (COC) Combined Use Study
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 20
- Registration Number
- NCT02852265
- Locations
- 🇺🇸
University of California, Davis, Sacramento, California, United States
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
- Conditions
- Moderate to Severe Primary Dysmenorrhea
- Interventions
- Drug: Placebo vaginal ring
- First Posted Date
- 2016-01-29
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 25
- Registration Number
- NCT02668783
Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
- Conditions
- Opiate AddictionPregnancyContraceptive BehaviorSexual Behavior
- Interventions
- Drug: Standard postpartum contraceptive care
- First Posted Date
- 2016-01-15
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 200
- Registration Number
- NCT02657148
- Locations
- 🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States
Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2017-08-14
- Lead Sponsor
- University of Campinas, Brazil
- Target Recruit Count
- 100
- Registration Number
- NCT02480647
- Locations
- 🇧🇷
Nelsilene Mota Carvalho, Campinas, São Paulo, Brazil
The Impact of Contraception on Postpartum Weight Loss
- Conditions
- Weight
- Interventions
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 100
- Registration Number
- NCT02144259
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2017-09-14
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 60
- Registration Number
- NCT02082652
- Locations
- 🇺🇬
Infectious Disease Institute, Kampala, Uganda
Quantification of Immune Cells in Women Using Contraception (CHIC II)
- Conditions
- HIVImmune Cells (Mucosal and Systemic)Contraception
- Interventions
- Device: subdermal contraceptive implant insertionDevice: IUD insertion
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 326
- Registration Number
- NCT01873170
- Locations
- 🇺🇸
Center for Family Planning Research, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.